Evidence map›Paper›PMID 22065657›Full record

ReviewBMJ (Clinical research ed.)2011

Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study.

Ioanna Tzoulaki, Konstantinos C M Siontis, John P A Ioannidis

Abstract readComparative StudyReview
In one paragraph

Review in BMJ (Clinical research ed.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Influence of food patterns on endothelial biomarkers: a systematic review.Journal of clinical hypertension (Greenwich, Conn.) · 2014
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Biomarkers of Cardiovascular Stress: A Historical Review.Journal of cardiovascular development and disease · 2026
    Review
  11. Review
  12. Tutorial: dos and don'ts in clinical prediction research for venous thromboembolism.Research and practice in thrombosis and haemostasis · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Cancer biomarker discovery and validation.Translational cancer research · 2015
    Article
  19. Article
  20. Meta-epidemiology.Epidemiology and health · 2014
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Ioanna TzoulakiDepartment of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
Konstantinos C M Siontis
John P A Ioannidis

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare the reported effect sizes of cardiovascular biomarkers in datasets from observational studies with those in datasets from randomised controlled trials.

designReview of meta-analyses. STUDY SELECTION: Meta-analyses of emerging cardiovascular biomarkers (not part of the Framingham risk score) that included datasets from at least one observational study and at least one randomised controlled trial were identified through Medline (last update, January 2011). DATA EXTRACTION: Study-specific risk ratios were extracted from all identified meta-analyses and synthesised with random effects for (a) all studies, and (b) separately for observational and for randomised controlled trial populations for comparison.

results31 eligible meta-analyses were identified. For seven major biomarkers (C reactive protein, non-HDL cholesterol, lipoprotein(a), post-load glucose, fibrinogen, B-type natriuretic peptide, and troponins), the prognostic effect was significantly stronger in datasets from observational studies than in datasets from randomised controlled trials. For five of the biomarkers the effect was less than half as strong in the randomised controlled trial datasets. Across all 31 meta-analyses, on average datasets from observational studies suggested larger prognostic effects than those from randomised controlled trials; from a random effects meta-analysis, the estimated average difference in the effect size was 24% (95% CI 7% to 40%) of the overall biomarker effect.

conclusionsCardiovascular biomarkers often have less promising results in the evidence derived from randomised controlled trials than from observational studies.

Indexed as

BiomarkersEpidemiologic StudiesObservationRandomized Controlled Trials as TopicBiasCardiovascular DiseasesHumansMeta-Analysis as TopicOdds RatioPrognosisBiomarkers

Identifiers

PMID22065657
PMCPMC3209745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.